{"prompt": "['Novartis', 'Confidential', 'Page 32', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'An investigator considers an interruption is necessary for the treatment of an adverse event.', 'Interruption to study drug must be recorded on the dosage administration record eCRF.', '5.5.6', 'Rescue medication', 'At Visit 1 all patients will be provided with a SABA (such as salbutamol [100 mcg]', 'or', 'albuterol [90 mcg]) which they will be instructed to use throughout the study as rescue', \"medication on an 'as needed basis. Patients will be advised that between visits they can take\", 'their rescue medication for symptoms of asthma. Rescue medication (i.e., SABAs) will either', 'be supplied to the study sites locally by Novartis or provided by the study site to the patient', 'and reimbursed by Novartis.', 'Nebulized salbutamol/albuterol is not allowed as rescue medication and will not be supplied.', 'No other rescue treatment is permitted and use of a spacer for rescue medication is not', 'allowed at any time throughout the study.', 'To standardize measurements, patients will be instructed not to use their rescue medication', 'upon rising in the morning on days requiring spirometric assessments in dicated in Table 6-1,', 'unless absolutely necessary. If rescue medication is taken within 6 hours prior to spirometry,', 'this information will be recorded by the study site staff using the equipment provide d by the', 'central spirometry vendor. Additionally, if rescue medication is taken within 6 hours prior to', 'spirometry at any of the scheduled visits, the visit must be rescheduled to the next possible', 'day.', 'Daily use of rescue medication (the number of puffs taken in the previous 12 hours) will be', 'recorded (once in the morning and once in the evening) by the patient using ePEF/ eDiary.', 'Unless clinically indicated, the type of rescue medication (i.e., SABA) a patient uses, the', 'device used to deliver the medication (e.g., dry powder or hydrofluoroalkane (HFA)) and the', 'way it is administered (e.g., with a spacer device) must not be adjusted. Any changes relating', 'to the above must be recorded on the Concomitant medications eCRF after the start of study', 'drug.', '5.5.7', 'Concomitant medication', 'The medications in Table 5-1 are only permitted under the circumstances given. This table', 'is', 'not considered all-inclusive. Medications should be assessed for adherence to the indication', 'and other inclusion/exclusion criteria.', 'Table 5-1', 'Medications allowed under certain conditions', 'Class of medication', 'Condition', 'Inhaled corticosteroids (ICS)', 'Medium dose ICS, or', 'High dose ICS, or', 'Low dose ICS plus LABA, or', 'Low dose ICS plus LTRA, or', 'Medium dose ICS plus LABA', 'Used for at least 3 months prior to Visit 1 and', 'dose(s) stable for at least 4 weeks prior to Visit 1.']['Novartis', 'Confidential', 'Page 33', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Dose adjustments are not permitted throughout the', 'study.', 'Long-acting inhaled \u00df-2 agonists (LABAs)', 'Allowed as the second asthma controller', 'medication when taken with low or medium dose', 'ICS.', 'Used for at least 3 months prior to Visit 1 and dose', 'stable for at least 4 weeks prior to Visit 1.', 'Dose adjustments are not permitted during the', 'study.', 'Fixed dose combinations of ICS and LABA', 'Allowed as ICS (low or medium dose) with a LABA.', '(FDC)', 'Used for at least 3 months prior to Visit 1 and', 'doses stable for at least 4 weeks prior to Visit 1.', 'Dose adjustments are not permitted during the', 'study.', 'Leukotriene receptor antagonists (LTRAs)', 'Allowed as the second asthma controller', 'medication when taken with low dose ICS.', 'Used for at least 3 months prior to Visit 1 and dose', 'stable for at least 4 weeks prior to Visit 1.', 'Dose adjustments are not permitted during the', 'study.', 'Oral corticosteroids for treatment of asthma', 'Short bursts of rescue systemic corticosteroids are', 'allowed for treatment of asthma exacerbations, as', 'clinically indicated.', 'Short-acting \u00df2-agonist (SABAs)', 'Rescue medication to be taken as needed.', 'Maintenance immunotherapy for allergies', 'Stable dose for at least 3 months prior to Visit 1', 'and the dose remains stable throughout the study.', 'Inactivated influenza vaccine,', 'Not administered within 48 hours prior to a study', 'pneumococcal vaccination or any other', 'visit.', 'inactivated vaccine', 'Topical corticosteroids for treatment of', 'Recommended doses and dosage regimens.', 'eczema', 'Antihistamines (e.g., loratadine, cetirizine)', 'Recommended doses and dosage regimens', 'Nasal anticholinergics', 'Nasal corticosteroids', 'Treatment regimen has been stable for at least 1', 'Nasal or ophthalmological preparations of', 'month prior to Visit 1.', 'nedocromil', 'In the case of as needed use, providing an', 'established pattern of use has been documented.', 'Nasal or ophthalmological preparations of', 'antihistamines', '*See Appendix 6 for the GINA 2016 definition of medium and high dose ICS.', 'Table 5-2 indicates the wash-out periods for allowed asthma medications prior to spirometry', 'assessments.']\n\n###\n\n", "completion": "END"}